Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: A randomized controlled trial

WHOM are you going to ask about this working for stroke spasticity? There is NO STROKE LEADER IN THE WORLD willing to talk to or take questions from survivors. Stroke associations don't give a shit about survivors, they are only there as pity pots to generate donations.  

I don't care that this was a failure in this instance, there is this:

This has been out there for years;
Nabiximols is an oromucosal spray formulated in a 1:1 ratio of tetrahydrocannabinol and cannabidiol and approved in several countries for treatment-resistant spasticity in patients with MS. It also works for motor neuron disease spasticity. (How fucking incompetent is your doctor in not using it?)

Do your prefer your incompetence NOT KNOWING? OR NOT DOING? OR BOTH?

Just maybe you want to get your doctor educated by reading these posts:

• nabiximols (5 posts to April 2013)

 

 

Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: A randomized controlled trial

Developmental Medicine & Child Neurology — Fairhurst C, Kumar R, Checketts D, et al. | April 30, 2020

Researchers conducted this multicentre, randomized, placebo‐controlled trial to evaluate the effectiveness, safety, and tolerability of oromucosal nabiximols cannabinoid medicine as adjunct therapy for children with spasticity due to cerebral palsy/traumatic central nervous system injury with inadequate response to existing treatment. In total, 72 individuals (mean [SD] age 12y 4mo [3y 1mo], range 8‒18y) were randomized at a ratio of 2:1 to receive nabiximols (n = 47; 29 males, 18 females) or placebo (n = 25; 15 males, 10 females) for 12 weeks (12 sprays/day max. based on clinical response/tolerability). Paediatric patients usually respond well to oromucosal nabiximols. Three cases of hallucinations, one of which involved auditory hallucinations and a suicide attempt, were however observed.  Oromucosal nabiximols compared with placebo did not minimize cerebral palsy/central nervous system injury‐related spasticity.

Read the full article on Developmental Medicine & Child Neurology